Plain-English translation of NCT06188676 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether adding nivolumab—a medication that helps your immune system fight cancer—to standard lymphoma chemotherapy improves outcomes for people newly diagnosed with primary mediastinal B-cell lymphoma. Some patients will receive chemotherapy alone (the current standard treatment), while others will receive chemotherapy plus the new medication. The goal is to see if the medication helps more patients recover from this type of lymphoma.
Primary mediastial B-cell lymphoma is a serious blood cancer that starts in the chest, and while standard chemotherapy helps some patients, doctors want to see if adding this medication to boost the immune system could help more people survive and stay cancer-free longer.
You likely qualify if…
You likely don't qualify if…
You will receive chemotherapy infusions as an outpatient over 5 days each cycle, with cycles repeating every 21 days for up to 6 rounds. If assigned to the treatment arm, you will also receive the new medication (nivolumab) by IV infusion. Throughout the trial, you'll have regular blood tests and imaging scans to check how well the treatment is working and monitor for side effects. The entire treatment phase typically lasts several months, followed by follow-up visits.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
Russia